Number of Employees: Around 280
Welcome to Philip Morris International’s (PMI) affiliates in Senegal, comprised of Philip Morris West Africa (PWWA) and Philip Morris Manufacturing Senegal (PMMSN).
For more than 20 years PMI has had a representative office in Senegal from where it managed its business in West and Central Africa region. In 2003, PMWA established its headquarters in Dakar. Today, PMWA provides support services to over 20 countries in the region where PMI products are sold.
PMMSN inaugurated a new factory in October 2009 which employs over 230 people. This facility manufactures products, including Marlboro, for domestic and export markets in the West and Central Africa region.
Investing in the community is a big part of our corporate culture. In recent years, we conducted two projects in disaster relief. In 2013, we will be in the process of developing an agricultural project aiming at reducing women work hardship in the area of Niayes – Pikine, Senegal.
Smoking and Health
Tobacco products, including cigarettes, are dangerous and addictive. There is overwhelming medical and scientific evidence that smoking causes lung cancer, heart disease, emphysema, and other serious diseases.
All tobacco products are addictive. It can be very difficult to quit smoking, but this should not deter smokers who want to quit from trying to do so.
Public health officials have concluded that secondhand smoke from cigarettes causes serious diseases in non-smokers, including lung cancer and heart disease. We believe the public health conclusions on secondhand smoke are sufficient to support smoking restrictions in public places.
Philip Morris International (PMI) supports comprehensive regulation of tobacco products based on the principle of harm reduction.
To be effective, tobacco regulatory policy must be evidence-based, apply to all tobacco products, and should take into account the views of all legitimate stakeholders including public health authorities, government finance authorities, tobacco manufacturers, and other members of the tobacco supply chain. Regulatory policy must consider the potential to trigger adverse consequences which undermine public health objectives, such as increasing the demand for illicit cigarettes.
While we support comprehensive, effective tobacco regulation, we do not support regulation that prevents adults from buying and using tobacco products or that imposes unnecessary impediments to the operation of the legitimate tobacco market. In that regard, we oppose measures such as generic packaging, point of sale display bans, total bans on communications to adult consumers, and bans on the use of all ingredients in tobacco products.